1-5 of 5
Naomi V Dahl, PharmD
Close
Sort by
Journal Articles

Severe Hypophosphatemia in Patients with Cancer Following IV Iron Treatment: Results from a Large Comparative Trial

Ralph V. Boccia, MD, Naomi V Dahl, PharmD, William E Strauss, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2236.
https://doi.org/10.1182/blood-2019-126149
Published: 2019
Journal Articles

Sustained Improvements in Fatigue and Quality of Life in Iron Deficiency Anemia Patients Following a Single Course of Ferumoxytol: Results of a 6-Month Extension Study

Saroj Vadhan-Raj, MD, Naomi V Dahl, PharmD, John Jiang, PhD, William E Strauss, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1050.
https://doi.org/10.1182/blood-2018-99-115511
Published: 2018
Journal Articles

Randomized, Double-Blind Trial of Ferumoxytol Compared to Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia: Safety and Efficacy

Michael Auerbach, MD, William E Strauss, MD, Iain C. Macdougall, MD, Kristine Bernard, MPH, Robert F Kaper, MD, Glenn M Chertow, MD MPH, Zhu Li, PhD, Anton Trochanov, MD, Naomi V Dahl, PharmD, Julie Krop, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3500.
https://doi.org/10.1182/blood.V130.Suppl_1.3500.3500
Published: 2017
Journal Articles

Is Thromboembolism in Cancer Patients Treated with Erythropoietic Stimulating Agents Related to Thrombocytosis and Iron Restricted Erythropoiesis?.

David H. Henry, MD, Naomi V. Dahl, PharmD, Michael Auerbach, MD
Journal: Blood
Blood (2007) 110 (11): 1625.
https://doi.org/10.1182/blood.V110.11.1625.1625
Published: 2007
Journal Articles

Intravenous Ferric Gluconate (FG) for Increasing Response to Epoetin (EPO) in Patients with Anemia of Cancer Chemotherapy - Results of a Multicenter, Randomized Trial.

David H. Henry, MD, Naomi V. Dahl, PharmD, Michael Auerbach, MD, Simon Tchekmedyian, MD, Leslie R. Laufman, MD, Ferrlecit Cancer Study Group
Journal: Blood
Blood (2004) 104 (11): 3696.
https://doi.org/10.1182/blood.V104.11.3696.3696
Published: 2004